source
- FDA places uniQure’s Huntington’s gene therapy in priority review, targeting May 2027 approvalThe U.S. Food and Drug Administration has accepted uniQure’s filing for its Huntington’s disease gene therapy and placed the product under priority review, a step that could accelerate a decision b…
- WuXi Biologics and Fresenius strike major deal for up to 37 biosimilars over the next decadeWuXi Biologics and German drugmaker Fresenius have agreed to collaborate on the development and manufacturing of up to 37 biosimilar medicines over the next ten years. The agreement is described a…